Accepted for Publication: October 20, 2021.
Published: December 15, 2021. doi:10.1001/jamanetworkopen.2021.38975
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Young-Xu Y et al. JAMA Network Open.
Corresponding Author: Yinong Young-Xu, ScD, White River Junction Veterans Affairs Medical Center, 215 N Main St, White River Junction, VT 05009 (firstname.lastname@example.org).
Author Contributions: Dr Young-Xu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Young-Xu, Smith.
Acquisition, analysis, or interpretation of data: Young-Xu, Zwain, Powell.
Drafting of the manuscript: Young-Xu, Zwain.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Young-Xu, Zwain, Smith.
Obtained funding: Young-Xu.
Administrative, technical, or material support: Young-Xu.
Conflict of Interest Disclosures: Dr Young-Xu and Mr Smith reported receiving funding from Pfizer. Ms Zwain reported receiving grants from the US Food and Drug Administration through an interagency agreement with the Veterans Health Administration and from the US Department of Veterans Affairs Office of Rural Health. Ms Zwain also reported receiving funding from Pfizer to her employer for other research projects outside the submitted work. Mr Powell reported receiving grants from the US Department of Veterans Affairs Office of Rural Health, the US Food and Drug Administration, and Pfizer. No other disclosures were reported.
Funding/Support: This project was funded by the US Department of Veterans Affairs Office of Rural Health.
Role of the Funder/Sponsor: The US Department of Veterans Affairs Office of Rural Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: This article represents the authors’ best judgement and should not bind or obligate the US Department of Veterans Affairs or any other institution.
KL , Dahl
RM , Prill
et al; SUPERNOVA COVID-19; Surveillance Group; Surveillance Platform for Enteric and Respiratory Infectious Organisms at the VA (SUPERNOVA) COVID-19 Surveillance Group. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalization—five Veterans Affairs medical centers, United States, February 1-August 6, 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(37):1294-1299. doi:10.15585/mmwr.mm7037e3